Company Xeno Transplants Corporation

Equities

XENO

US98410N1072

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Share class

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:38:02 2024-05-10 EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	0.00%

Xeno Transplants Corporation, formerly Icon Development, Inc., is a bio-technology research and development company that holds an exclusive commercial license from Massachusetts General Hospital derived from over 15 years of development in the field of xenotransplantation by Novartis Pharmaceuticals and its associated research entities. The Company intends to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to limited human donor sources.

USD in Million	2006	Weight	2007	Weight	Delta
Smart Office Software nan %	0	nan %	0	nan %	+-NaN%

USD in Million	2006	Weight	2007	Weight	Delta
United States nan %	0	nan %	0	nan %	+-NaN%

Managers	Title	Age	Since
Wayne Nathan Smith DFI	Director of Finance/CFO	63	07-02-01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	40,363,822	31,100,000 ( 77.05 %)	0	77.05 %

Xeno Transplants Corp.

1066 West Hastings Street Suite 2610

V6E 3X2, Vancouver

address Xeno Transplants Corporation(XENO)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
XENO TRANSPLANTS CORPORATION	0.00%	4.04K
MODERNA, INC.	+33.63%	50.85B
IQVIA HOLDINGS INC.	-0.09%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B
BIO-TECHNE CORPORATION	+8.61%	13.05B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B

Other Biotechnology & Medical Research